Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jul 2

PMID 34201007

Citations 9

Authors

Kinan Alhallak

Jennifer Sun

Amanda Jeske

Chaelee Park

Jessica Yavner

Hannah Bash

Berit Lubben

Ola Adebayo

Ayah Khaskiah

Abdel Kareem Azab

Affiliations

Soon will be listed here.

Abstract

MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.

Citing Articles

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment.

Navab R, Futela P, Kumari V, Valecha J, Gupta R, Jain R Iran J Med Sci. 2025; 50(1):1-10.

PMID: 39957814 PMC: 11829063. DOI: 10.30476/ijms.2024.101739.3446.

Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma.

Springer A, Wang R, Wang J, Du Q, Pi W, Nguyen A Cancer Res Commun. 2024; 4(10):2660-2672.

PMID: 39292169 PMC: 11467701. DOI: 10.1158/2767-9764.CRC-24-0413.

IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma.

Sun J, Corradini S, Azab F, Shokeen M, Muz B, Miari K Leukemia. 2024; 38(11):2355-2365.

PMID: 39215060 PMC: 11518999. DOI: 10.1038/s41375-024-02391-8.

Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma.

Grab A, Kim P, John L, Bisht K, Wang H, Baumann A Cells. 2024; 13(10.

PMID: 38786100 PMC: 11120574. DOI: 10.3390/cells13100879.

Multiple Myeloma: A Review of the Literature and a Case Report Highlighting the Immunocompromised State of Myeloma Patients.

Nightingale B, Decker M, Ryan R, Kaczmarczyk K, Jandir P, Waykole T World J Oncol. 2024; 15(3):348-354.

PMID: 38751697 PMC: 11092413. DOI: 10.14740/wjon1780.

References

Tai Y, Mayes P, Acharya C, Zhong M, Cea M, Cagnetta A . Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-38. PMC: 4023420. DOI: 10.1182/blood-2013-10-535088. View

Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A . Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin Pharmacokinet. 2016; 55(10):1271-1288. DOI: 10.1007/s40262-016-0405-4. View

Li J, Stagg N, Johnston J, Harris M, Menzies S, DiCara D . Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. Cancer Cell. 2017; 31(3):383-395. PMC: 5357723. DOI: 10.1016/j.ccell.2017.02.001. View

Ellerman D . Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2018; 154:102-117. DOI: 10.1016/j.ymeth.2018.10.026. View

Cohen A, Garfall A, Stadtmauer E, Melenhorst J, Lacey S, Lancaster E . B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019; 129(6):2210-2221. PMC: 6546468. DOI: 10.1172/JCI126397. View

Leenaars M, Hendriksen C . Critical steps in the production of polyclonal and monoclonal antibodies: evaluation and recommendations. ILAR J. 2005; 46(3):269-79. DOI: 10.1093/ilar.46.3.269. View

Polson A, Zheng B, Elkins K, Chang W, Du C, Dowd P . Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol. 2006; 18(9):1363-73. DOI: 10.1093/intimm/dxl069. View

Costa F, Palma B, Giuliani N . CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents. Cells. 2019; 8(12). PMC: 6952797. DOI: 10.3390/cells8121632. View

Gharbaran R . Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies. Crit Rev Oncol Hematol. 2015; 94(1):1-17. DOI: 10.1016/j.critrevonc.2014.12.003. View

10.

Schuh E, Musumeci A, Thaler F, Laurent S, Ellwart J, Hohlfeld R . Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement. J Immunol. 2017; 198(8):3081-3088. DOI: 10.4049/jimmunol.1601746. View

11.

Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T . Design and Production of Bispecific Antibodies. Antibodies (Basel). 2019; 8(3). PMC: 6783844. DOI: 10.3390/antib8030043. View

12.

Goldstein R, Goyos A, Li C, Deegen P, Bogner P, Sternjak A . AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020; 4(17):4180-4194. PMC: 7479952. DOI: 10.1182/bloodadvances.2020002565. View

13.

Cohen A, Raje N, Fowler J, Mezzi K, Scott E, Dhodapkar M . How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. Clin Cancer Res. 2019; 26(7):1541-1554. PMC: 8176627. DOI: 10.1158/1078-0432.CCR-19-2111. View

14.

Ghermezi M, Li M, Vardanyan S, Harutyunyan N, Gottlieb J, Berenson A . Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2016; 102(4):785-795. PMC: 5395119. DOI: 10.3324/haematol.2016.150896. View

15.

Baeuerle P, Reinhardt C . Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009; 69(12):4941-4. DOI: 10.1158/0008-5472.CAN-09-0547. View

16.

Stieglmaier J, Benjamin J, Nagorsen D . Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin Biol Ther. 2015; 15(8):1093-9. DOI: 10.1517/14712598.2015.1041373. View

17.

Laubach J, Richardson P, Anderson K . Multiple myeloma. Annu Rev Med. 2010; 62:249-64. DOI: 10.1146/annurev-med-070209-175325. View

18.

Fang Y, Hou J . Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma. Mil Med Res. 2021; 8(1):9. PMC: 7839214. DOI: 10.1186/s40779-021-00302-x. View

19.

Yuraszeck T, Kasichayanula S, Benjamin J . Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment. Clin Pharmacol Ther. 2017; 101(5):634-645. PMC: 5763312. DOI: 10.1002/cpt.651. View

20.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View